Peptide targeted radiotherapy – a promising new approach to cancer therapy.
Our targeted therapy has been widely validated in clinical studies as well as in routine clinical use in Europe. Learn More
News from Andarix
- Andarix Pharmaceuticals CEO to Chair Radiopharmaceutical Conference
February 26, 2025 Targeted Radiotherapies: A New Approach to Treating Cancer Boston — ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams, will chair a session at the targeted therapy conference in Boston. The conference will… Read more: Andarix Pharmaceuticals CEO to Chair Radiopharmaceutical Conference - Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical… Read more: Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference - Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include… Read more: Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference